Search results for "Tatin"

showing 10 items of 700 documents

Intensive LDL-cholesterol lowering therapy and neurocognitive function

2017

The key lipid-lowering target is to achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) levels, usually by using statins. The new treatment strategies for lipid-lowering therapy include using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as an exciting approach to reduce residual risk of cardiovascular diseases (CVD). However, concerns about possible adverse effects, including neurocognitive disorders, were issued by the Food and Drug Administration (FDA). The current disputable evidence does not allow definite conclusions as to whether statins contribute to, or cause, clinically meaningful cognitive impairment. Some evidence indicates a high rate of…

MaleApolipoprotein Emedicine.medical_specialtyStatinmedicine.drug_classNeurocognitive DisordersProprotein convertase subtilisin/kexin type 9030204 cardiovascular system & hematologyBioinformatics03 medical and health sciencesCognitionSex Factors0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLipid-lowering drugAnimalsDementiaLow-density lipoprotein cholesterolAge FactorPharmacology (medical)Adverse effectHypolipidemic AgentsPharmacologybusiness.industryPCSK9PCSK9 InhibitorsAge FactorsStatinCognitionCholesterol LDLmedicine.diseaseNeurocognitive functionResidual riskEndocrinologyFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessNeurocognitive030217 neurology & neurosurgeryPharmacology & Therapeutics
researchProduct

Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to eto…

1999

BACKGROUND The mechanisms of drug resistance associated with advanced, hormone-independent prostate carcinoma are poorly understood. The human prostate carcinoma PC-3 cell line, derived from a metastatic tumor and lacking androgen receptors, represents a useful model to investigate drug resistance. METHODS The effects of oncostatin M (OM), antiinterleukin-6 (IL-6) treatment, or interference with the gp130-mediated signaling on etoposide- or cisplatin-mediated cytotoxicity were investigated. RESULTS Both endogenous and exogenous IL-6 and exogenous OM up-regulated cell growth and enhanced resistance of PC-3 tumor cells to both etoposide and cisplatin. The influence of IL-6 is controlled by tr…

MaleCancer Researchmedicine.drug_classAntineoplastic AgentsOncostatin MBiologyCell surface receptorAntigens CDCyclohexenesmedicineCytokine Receptor gp130Tumor Cells CulturedHumansReceptorEtoposideEtoposideMembrane GlycoproteinsCell growthInterleukin-6TerpenesOncostatin MProstatic NeoplasmsGlycoprotein 130Receptor antagonistAntineoplastic Agents PhytogenicGenisteinOncologyDrug Resistance NeoplasmCancer researchbiology.proteinMonoterpenesSignal transductionCisplatinPeptidesmedicine.drugSignal Transduction
researchProduct

Serum follistatin in patients with prostate cancer metastatic to the bone

2010

The clinical significance of circulating fol- listatin (FLST), an inhibitor of the multifunctional cytokine activin A (Act A), was investigated in patients with prostate cancer (PCa). The serum concentrations of this molecule were determined by an enzyme-linked immunosorbent assay (ELISA) in PCa patients with (M?) or without (M0) bone metastases, in patients with benign prostate hyperplasia (BPH) and in healthy sub- jects (HS). The effectiveness of FLST in detecting PCa patients with skeletal metastases was determined by the receiver operating characteristic (ROC) curve analysis. Serum FLST was significantly higher in PCa patients than in BPH patients (P = 0.001) or HS (P = 0.011). Converse…

MaleCancer Researchmedicine.medical_specialtyFollistatinBone diseaseSettore MED/06 - Oncologia MedicaBone metastasis cancer follistatin prostate cancer transforming growth factor beta tumor markersBone Neoplasmsurologic and male genital diseasesGastroenterologySensitivity and SpecificityProstate cancerInternal medicineMedicineHumansClinical significanceAgedHematologybusiness.industryCancerBone metastasisProstatic NeoplasmsGeneral MedicineHyperplasiaMiddle AgedProstate-Specific Antigenmedicine.diseaseActivinsProstate-specific antigenEndocrinologyOncologySettore BIO/14 - Farmacologiabusiness
researchProduct

Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.

2008

The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from breast cancer (BCa) or prostate cancer (PCa). Additional studies were also performed in these patients to assess the effects of zoledronic acid (ZA) administration on the circulating levels of these molecules. Mean IL-6 and Cyst C serum concentrations were signifi- cantly increased in BCa patients and in patients with primary osteoporosis (PU) compared to healthy subjects (HS). However, Cyst C, but not IL-6, resulted significantly more elevated in BCa patients t…

MaleCancer Researchmedicine.medical_specialtyPathologyBone diseasemedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsZoledronic AcidGastroenterologyProstate cancercancer metastatic bone disease cystatin cInternal medicineBiomarkers TumormedicineHumansCystCystatin CAgedAged 80 and overBone Density Conservation AgentsDiphosphonatesbiologyInterleukin-6business.industryImidazolesProstatic NeoplasmsCancerBone metastasisHematologyGeneral MedicineMiddle AgedProstate-Specific AntigenBisphosphonatemedicine.diseaseZoledronic acidROC CurveOncologyCystatin Cbiology.proteinOsteoporosisFemalebusinessmedicine.drug
researchProduct

Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease : results from the EUROASPIRE IV …

2018

Background: This study aims to assess the cost-effectiveness of optimized guideline adherence in patients with a history of coronary heart disease. Methods: An individual-based decision tree model was developed using the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease (CVD). Analyses were based on the EUROASPIRE IV survey. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). Results: Data from 4663 patients from 13 European countries were included in the analyses. The mean estimated 10-year risk for a recurrent vascular event decreased from 20.13% to 18.61% after optimized guideline a…

MaleCardiac & Cardiovascular SystemsCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisCoronary DiseaseDisease030204 cardiovascular system & hematology0302 clinical medicineOlder patientsMedicine030212 general & internal medicineguidelinesEUROASPIRE1102 Cardiorespiratory Medicine and Haematologyhealth care economics and organizationsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Framingham Risk ScoreSecondary preventionASSOCIATIONMiddle AgedhumanitiesCoronary heart diseaseEuropeDENSITY-LIPOPROTEIN CHOLESTEROLPractice Guidelines as TopicTRIALFemaleGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary prevention ; guidelines ; cost-effectiveness ; coronary heart disease ; EUROASPIREsecondary preventionmedicine.drugINTERVENTIONSmedicine.medical_specialtyEZETIMIBEGuidelinesEVENTS03 medical and health sciencesEzetimibeInternal medicineHumansIn patientcoronary heart diseaseBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.cost-effectivenessMETAANALYSISAgedScience & Technologybusiness.industryDecision TreesSMOKING-CESSATIONCoronary heart diseaseTHRESHOLDSCardiovascular System & HematologyCardiovascular System & CardiologySmoking cessationCost-effectivenessbusinessSTATIN TREATMENT
researchProduct

Growth Differentiation Factor-15 (GDF-15) Levels Are Associated with Cardiac and Renal Injury in Patients Undergoing Coronary Artery Bypass Grafting …

2014

International audience; Objective: Growth differentiation factor-15 (GDF-15) has been identified as a strong marker of cardiovascular disease; however, no data are available concerning the role of GDF-15 in the occurrence of organ dysfunction during coronary artery bypass grafting (CABG) associated with cardiopulmonary bypass (CPB). Methods: Five arterial blood samples were taken sequentially in 34 patients from anesthesia induction (IND) until 24 h after arrival at the intensive care unit (ICU). Plasma levels of GDF-15, follistatin-like 1 (FLST1), myeloperoxidases (MPO), hydroperoxides and plasma antioxidant status (PAS) were measured at each time-point. Markers of cardiac (cardiac-troponi…

MaleCardiothoracic SurgeryCardiovascular ProceduresGeneral Anesthesialcsh:Medicine030204 cardiovascular system & hematologyAntioxidantslaw.inventionPostoperative Complications0302 clinical medicineAnesthesiologylawTroponin IMedicine and Health SciencesCoronary Heart DiseaseMedicineAnesthesiaCoronary Artery Bypasslcsh:Science0303 health sciencesCardiopulmonary BypassCoronary Artery Bypass GraftingMultidisciplinaryAcute kidney injuryAcute Kidney InjuryMiddle AgedLipocalins[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthCardiac surgeryIntensive Care UnitsCardiovascular Diseasesembryonic structuresCardiologyArterial bloodFemalemedicine.symptomResearch Articlemedicine.medical_specialtyFollistatin-Related ProteinsGrowth Differentiation Factor 15Heart DiseasesCardiac SurgeryCardiologyRenal functionSurgical and Invasive Medical Procedures03 medical and health sciencesLipocalin-2[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPredictive Value of TestsProto-Oncogene ProteinsInternal medicineCardiopulmonary bypassHumansAgedPeroxidase030304 developmental biologybusiness.industryTroponin Ilcsh:ROrgan dysfunctionHydrogen Peroxidemedicine.diseaseSurgerylcsh:QGDF15businessBiomarkersAcute-Phase Proteins
researchProduct

Statins and other drugs: Facing COVID-19 as a vascular disease

2020

Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes.We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The …

MaleCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAngiotensin-Converting Enzyme InhibitorsRisk AssessmentSeverity of Illness IndexCohort StudiesBetacoronavirusAngiotensin Receptor AntagonistsBelgiumStatins Drugs COVID-19 Vascular DiseaseCause of DeathVascular DiseasePandemicOdds RatioHomes for the AgedHumansMedicineVascular DiseasesLetter to the EditorGeriatric AssessmentPandemicsAgedRetrospective StudiesAged 80 and overPharmacologybiologySARS-CoV-2business.industryVascular diseaseStatinsDrugsCOVID-19medicine.diseasebiology.organism_classificationVirologyNursing HomesSurvival RatePneumoniaLogistic ModelsTreatment OutcomeFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCoronavirus InfectionsbusinessNursing homesCoronavirus InfectionsBetacoronavirusPharmacological Research
researchProduct

Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro

2011

Glucagon-like peptide-1 (GLP-1) acts at the G protein-coupled receptor, GLP-1R, to stimulate secretion of insulin and to inhibit secretion of glucagon and gastric acid. Involvement in mucosal secretory physiology has received negligible attention. We aimed to study involvement of GLP-1 in mucosal chloride secretion in the small intestine. Ussing chamber methods, in concert with transmural electrical field stimulation (EFS), were used to study actions on neurogenic chloride secretion. ELISA was used to study GLP-1R effects on neural release of acetylcholine (ACh). Intramural localization of GLP-1R was assessed with immunohistochemistry. Application of GLP-1 to serosal or mucosal sides of fla…

MaleCytoplasmendocrine systemmedicine.medical_specialtyReceptors Vasoactive Intestinal Polypeptide Type IPhysiologyGuinea PigsScopolamineVasoactive intestinal peptideHormones and SignalingIleumIn Vitro TechniquesHexamethoniumGlucagonGlucagon-Like Peptide-1 ReceptorCholine O-AcetyltransferaseGuinea pigChloridesGlucagon-Like Peptide 1IleumPhysiology (medical)Internal medicineIntestine SmallReceptors GlucagonmedicineAnimalsNeuropeptide YSecretionIntestinal MucosaNeuronsHepatologyChemistrydigestive oral and skin physiologyElectric ConductivityGastroenterologyAcetylcholineElectric StimulationPeptide FragmentsSmall intestineElectrophysiological PhenomenaEndocrinologymedicine.anatomical_structureSomatostatinELAV ProteinsGastric acidCarbacholSomatostatinhormones hormone substitutes and hormone antagonistsVasoactive Intestinal PeptideAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

The dendritic spines of interneurons are dynamic structures influenced by PSA-NCAM expression.

2013

Excitatory neurons undergo dendritic spine remodeling in response to different stimuli. However, there is scarce information about this type of plasticity in interneurons. The polysialylated form of the neural cell adhesion molecule (PSA-NCAM) is a good candidate to mediate this plasticity as it participates in neuronal remodeling and is expressed by some mature cortical interneurons, which have reduced dendritic arborization, spine density, and synaptic input. To study the connectivity of the dendritic spines of interneurons and the influence of PSA-NCAM on their dynamics, we have analyzed these structures in a subpopulation of fluorescent spiny interneurons in the hippocampus of glutamic …

MaleDendritic spineTime FactorsInterneuronCognitive NeuroscienceDendritic SpinesGreen Fluorescent ProteinsHippocampusNeuraminidaseMice TransgenicNerve Tissue ProteinsNeural Cell Adhesion Molecule L1BiologyHippocampal formationIn Vitro TechniquesHippocampus03 medical and health sciencesCellular and Molecular NeuroscienceMice0302 clinical medicineOrgan Culture TechniquesInterneuronsmedicineAnimals030304 developmental biology0303 health sciencesPolysialic acidGlutamate DecarboxylaseDendritic filopodiamedicine.anatomical_structurenervous systemAnimals NewbornGene Expression RegulationCalbindin 2Excitatory postsynaptic potentialSialic AcidsNeural cell adhesion moleculeCholecystokininSomatostatinNeuroscience030217 neurology & neurosurgeryVasoactive Intestinal PeptideCerebral cortex (New York, N.Y. : 1991)
researchProduct

Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia—the effects of blocking myostatin and activins

2020

Objective Cancer cachexia and muscle loss are associated with increased morbidity and mortality. In preclinical animal models, blocking activin receptor (ACVR) ligands has improved survival and prevented muscle wasting in cancer cachexia without an effect on tumour growth. However, the underlying mechanisms are poorly understood. This study aimed to identify cancer cachexia and soluble ACVR (sACVR) administration-evoked changes in muscle proteome. Methods Healthy and C26 tumour-bearing (TB) mice were treated with recombinant sACVR. The sACVR or PBS control were administered either prior to the tumour formation or by continued administration before and after tumour formation. Muscles were an…

MaleEXPRESSIONActivin receptor; APR; C26; Cancer cachexia; Nrk2; OXPHOSlcsh:Internal medicineCachexiaREVERSALActivin ReceptorsMETABOLISMactivin receptorOxidative PhosphorylationCell Line TumorAnimalsMuscle Skeletallcsh:RC31-1245aineenvaihduntaSerpinslihassolut318 Medical biotechnologyNrk2Cancer cachexiaMyostatinNADOXPHOSMUSCULAR-DYSTROPHYActivinsMitochondriaActivin receptorDisease Models AnimalMuscular AtrophyMICESIRTUINSOriginal ArticlesyöpätauditproteiinitC26lihassurkastumasairaudetAPRAcute-Phase Proteinscancer cachexia
researchProduct